Financial Ratios

MEDICAMEN BIOTECH LTD.

NSE : MEDICAMEQBSE : 531146ISIN CODE : INE646B01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE491.3060.4 (+14.02 %)
PREV CLOSE ( ) 430.90
OPEN PRICE ( ) 428.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 12595
TODAY'S LOW / HIGH ( )428.90 496.00
52 WK LOW / HIGH ( )356.75 903.5
NSE485.8563.75 (+15.1 %)
PREV CLOSE( ) 422.10
OPEN PRICE ( ) 424.30
BID PRICE (QTY) 485.85 (4989)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 149878
TODAY'S LOW / HIGH( ) 424.30 495.40
52 WK LOW / HIGH ( )355.45 845
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)11.8612.2010.2210.0310.28
   CEPS(Rs)16.8816.9312.2812.0812.17
   DPS(Rs)1.001.001.000.501.00
   Book NAV/Share(Rs)147.68114.84104.5298.5873.69
   Tax Rate(%)13.4517.6625.4626.1731.37
Margin Ratios
   Core EBITDA Margin(%)17.8520.8718.1815.4514.24
   EBIT Margin(%)15.0317.3616.5814.9415.42
   Pre Tax Margin(%)12.5715.6815.2114.1514.29
   PAT Margin (%)10.8812.9111.3410.459.81
   Cash Profit Margin (%)15.4917.9113.6212.5811.61
Performance Ratios
   ROA(%)6.007.146.777.839.46
   ROE(%)9.1711.1210.0611.8614.96
   ROCE(%)10.9512.8213.1215.2620.22
   Asset Turnover(x)0.550.550.600.750.96
   Sales/Fixed Asset(x)1.080.961.272.252.65
   Working Capital/Sales(x)1.782.322.612.502.57
Efficiency Ratios
   Fixed Capital/Sales(x)0.921.040.790.440.38
   Receivable days160.69175.37155.22135.78121.75
   Inventory Days95.3950.9236.7250.1143.90
   Payable days302.49299.07236.52191.32137.99
Valuation Parameters
   PER(x)55.2852.7552.2518.0147.18
   PCE(x)38.8438.0343.4714.9639.84
   Price/Book(x)4.445.605.111.836.58
   Yield(%)0.150.160.190.280.21
   EV/Net Sales(x)6.057.006.071.964.65
   EV/Core EBITDA(x)30.8231.3132.1511.4827.02
   EV/EBIT(x)40.2740.3336.5813.1230.18
   EV/CE(x)3.043.593.471.304.18
   M Cap / Sales6.016.815.921.884.63
Growth Ratio
   Net Sales Growth(%)19.444.81-6.13-4.299.95
   Core EBITDA Growth(%)4.8924.223.74-5.1413.12
   EBIT Growth(%)3.399.754.15-7.2513.80
   PAT Growth(%)0.6419.381.861.9418.92
   EPS Growth(%)-2.8219.381.86-2.3718.92
Financial Stability Ratios
   Total Debt/Equity(x)0.140.180.150.100.14
   Current Ratio(x)1.961.701.841.931.98
   Quick Ratio(x)1.481.361.741.591.67
   Interest Cover(x)6.1110.3312.0818.8313.68
   Total Debt/Mcap(x)0.030.030.030.050.02

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.